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The synthesis of aspirin in the late
nineteenth century marked the
development of what was to become
the most widely used household
analgesic in the twentieth century.
However, with the increased
understanding of the major role of
platelets in vascular occlusion over the
last ten years, the importance of
aspirin as an antiplatelet drug and,
consequently, its applications in
reducing the risks of thrombotic
vascular events, have received major
attention.
Pharmacology
and Mechanism of Action
Aspirin, otherwise known as
acetylsalicylic acid, acts by acetylation
of the two isoenzyme forms of
prostaglandin G/H synthase. This
results in the irreversible inactivation
of the cyclooxygenase activity of this
enzyme, preventing the conversion of
arachidonic acid to prostaglandin G2,
and consequently decreasing
biosynthesis of prostaglandin H2 and
thromboxane A2. The type one
isoenzyme of prostaglandin G/H
synthase is constitutively expressed in
platelets, where synthesis and release
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of thromboxane A2 occurs in response
to a variety of stimuli, resulting in
irreversible platelet aggregation.
Platelets, platelet products and
thombosis play important roles in the
occurrence of acute occlusive vascular
events, including myocardial infarction
(MI) and ischemic stroke, since the
disruption of platelet- and fibrin-rich
atheroschlerotic plaque may be
followed by aggressive platelet
deposition and, ultimately the
development of a thrombus that can
precipitate an acute occlusive event.
The decreased platelet aggregation
caused by aspirin is  the most plausible
mechanism for the cardioprotective
effects of this drug.
Dose-dependant inhibition of
platelet cyclooxygenase activity occurs
with single aspirin oral doses of 5 to
100 mg, with the latter dose resulting
in practically total suppression of
thromboxane A2 biosynthesis. The onset
of activity of the drug is extremely
rapid and unrelated to systemic
bioavailability, probably due to platelet
prostaglandin synthase suppression in
the portal circulation. Furthermore,
since platelets lack the intracellular
machinery necessary to regenerate
prostaglandin synthase, recovery from
the effects of aspirin is related to
platelet turnover (7 to 10 days), with
repeated doses exerting a cumulative
effect. This accounts for the fact that a
drug with a half-life of 20 minutes is
effective even when administered once
daily.
Primary Prevention
of Occlusive
Cardiovascular Disease
The efficacy of aspirin at preventing
important cardiovascular events, chiefly
myocardial infaction, stroke and
cardiovascular mortality has been
assessed in healthy subjects and
subjects with stable chronic angina.
Also, since patients with insulin-
dependent and non-insulin-dependent
diabetes mellitus, and hypertensive
individuals have an increased risk of
cardiovascular complications, including
myocardial infarction and stroke, these
categories of patients have also
received attention in studies assessing
the antiplatelet activity of aspirin. The
results of these studies are summarised
in Table 1.
Despite the significant reduction in
MI incidence noted in the Physicians’
Health Study, the benefit of aspirin in
healthy individuals appears to be minor,
given the very low absolute risk of
cardiovascular events in healthy
individuals (only 5% had an event
during approximately 5 years of follow-
up). However, in patients with an
existing medical condition predisposing
to a cardiovascular event, the use of
aspirin appeared to have significant
benefits. In particular, in the medium-
risk population investigated in the
Swedish Angina Pectoris Aspirin Trial,
the results suggested the potential to
prevent 51 important cardiovascular
events in 1000 patients over four years,
an absolute benefit at least tenfold
greater than that obtained in the
British Doctors’ Trial and the Physicians’
Health Study. Similar benefits were also
observed in hypertensive patients.
Secondary Prevention of
Occlusive Vascular Disease
The benefits afforded by aspirin in
the prevention of secondary
cardiovascular events supercede those
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Study Type of Subjects Number of Patients Aspirin Dose Outcome
British Doctors’ Trial Healthy males, 5,139 500 mg daily No significant difference
50-78 yrs old vs placebo
Physicians’ Health Healthy males, 22,071 325 mg every 39% decrease in MI;
Study (USA) 40-84 yrs old other day 18% decrease in important
vs placebo cardiovascular events
Swedish Angina Patients with chronic 2,035 75 mg daily 34% decrease in MI and sudden
Pectoris Aspirin Trial stable angina without vs placebo death occurrence;
previous MI 22 - 32% decrease
in secondary outcomes
Early Treatment Patients with diabetes, 3,711 650 mg daily 28% decrease in MI,
Diabetic Retinopathy 49% of whom with vs placebo 16% increase in stroke,
Study cardiovascular disease 18% decrease in important
history cardiovascular events
Hypertension Optimal Hypertensive patients 18,790 75 mg daily 36% decrease in MI,
Treatment Trial (diastolic BP100-115 mmHg), vs placebo 15% decrease in major
50-80 yrs old cardiovascular events
Table 1: Trials of Aspirin in the Primary Prevention of Occlusive Cardiovascular Disease.
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for primary events. The drug remains
the standard antiplatelet reference
compound for secondary prevention of
myocardial infarction, cardiovascular-
associated death, and stroke. To this
date, no other antiplatelet agent can
compete with aspirin in these
indications. Three main areas, in
increasing order of severity, have been
identified where the antiplatelet
activity of aspirin plays a significant
role in preventing secondary
cardiovascular events. These are:
a) unstable angina and nonacute
myocardial infarction
b) suspected acute evolving myocardial
infarction and acute nonfatal
myocardial infarction, and
c) transient cerebral ischaemia and
stroke.
Three major studies all established
that the administration of aspirin, both
short- and long-term, was particularly
effective at reducing the risk of acute
myocardial infarction and/or death
(Table 2). Subgroup analysis in the RISC
study also showed that the risk of
myocardial infarction was reduced both
in patients with silent ischaemia as
well as in those with asymptomatic
ischaemia detected during a
presdischarge exercise test. However,
doubt remains as to whether aspirin
can affect the incidence or severity of
myocardial ischaemia after an episode
of unstable angina. However, the drug
did reduce incidence of death and
myocardial infarction in patients with
this syndrome, regardless of any
influence on episodes of transient
ischaemia.
Although the results of most early
studies in the benefits of aspirin
against secondary cardiovascular events
in patients with suspected acute
evolving myocardial infarction and
acute nonfatal myocardial infarction
were consistent with the benefits of
antiplatelet therapy, most trials were
too small individually in sample size. In
1988, an overview was published by the
Antiplatelets Trialists’ Collaboration of
the 25 completed trials in secondary
prevention, followed by an updated
overview in 1994. The results are
summarised in Table 3 and, together
with those of the Second International
Study of Infarct Survival, demonstrate
the effectiveness of antiplatelet
treatment in promoting survival
following myocardial infarction.
Moreover, in the latter study, the
combination of aspirin with intravenous
streptokinase proved to be more
effective than either agent alone. In
absolute terms, the percentage
reductions observed imply that the
treatment of 1000 patients with acute
myocardial infarction with aspirin for
one month would prevent 38 fatal and
nonfatal cardiovascular events.
The efficacy of aspirin in reducing
the risk of recurrent vascular
complications in patients with a history
of transient ischaemic attacks or stroke
was evaluated in various trials. An
overview of these trials carried out by
the Antiplatelets Trialists’ Collaboration
concluded that the administration of
antiplatelet therapy for three years was
effective at reducing the risk of
nonfatal stroke, nonfatal myocardial
infarction and cardiovascular death by
about 25%, respresting, in absolute
terms, the prevention of 37
cardiovascular events per 1000 patients
over three years. Some doubt remains
over the magnitude of the aspirin dose
which is effective; while some
investigators claim that larger doses
are more effective, patients receiving
larger doses in those studies reporting
a beneficial effect were also receiving
other antiplatelet drugs, in particular
dipyridamole and sulfinpyrazone.
Maintenance of Vascular
Grafts or Arterial Patency
A further outcome of the overview
conducted by the Antiplatelets Trialists’
Collaboration was the evidence of the
benefits provided by antiplatelet
therapy in reducing the incidence of
arterial or graft occlusion after
coronary-artery surgery (30% decrease)
or angioplasty (50% decrease), and
after the formation of a haemodialysis
shunt or fistula (56% decrease). The
data provided represented absolute
benefits of 90 patients protected per
1000 over 7 months following coronary
artery surgery, 40 patients per 1000
over 6 months following angioplasty,
and 200 patients per 1000 over two
months following formation of a
haemodialysis shunt. The same group
also concluded that antiplatelet therapy
was effective at reducing the incidence
of deep vein thrombosis and pulmonary
embolism by 26% and 64% respectively,
respresenting absolute prevention in 90
and 17 patients, respectively, per 1000
treated. While effective prevention was
observed in a wide range of medical
and surgical patients, the highest
benefits were seen in general and
orthopaedic surgery.
Side Effects and Safety of
Antiplatelet Therapy with
Aspirin
The regulation of several
homeostatic mechanisms, including
haemostasis, renal function, gastric
acid secretion and blood pressure
control, is modulated locally through
eicosanoid synthesis. Inhibition of the
constitutive prostaglandin G/H
synthase pathway responsible for the
production of these mediators is
essentially responsible for the side
effects associated with the long term
administration of aspirin.
Gastrointestinal complications, such
as bleeding and perforation, are
observed with greater frequency in
individuals on nonsteroidal
antiinflammatory therapy. The
incidence and severity of these
complications are effected by the
dosage regimen, the duration of
treatment and the type of formulation
used (plain vs enteric-coated).
Comparison of daily doses of 900 to
1300 mg daily (300 or 325 mg three
times daily) as against placebo for
various studies exhibited a 40 to 60%
increased incidence of stomach pain,
heartburn and nausea. On the other
hand, both the Veterans Administration
Cooperative Study and the Research
Group on Instability in Coronary Artery
Disease in Southeast Sweden (Table 2)
noted only minor increases in the
frequency of gastrointestinal symptoms
with daily doses of 324 mg and 75 mg
aspirin, respectively. Similar dose-
dependant results were also obtained
by the United Kingdom Transient
Ischaemic Attack (UK-TIA) Trial, which
noted a 19% increase in upper
gastrointestinal symptoms in patients
given 300 mg aspirin daily over
placebo, and a 58% increase in patients
given 1200 mg daily.
The incidence of haemorrhagic
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Table 2: Percent reductions in risk of death or acute myocardial infarction in trials among patients following
episodes of unstable angina or nonacute myocardial infarction.
Study Type of Subjects Aspirin Regimen Percent reduction
Research Group on Instability 796 male patients 75 mg daily for 5 days 57-69%
in Coronary Artery Disease in 75 mg daily for 3 months 64%
Southeast Sweden (RISC) 75 mg daily for 1 year 48%
Veterans Administration 1,266 male patients 324 mg daily for 3 months 51%
Cooperative Study
Canadian Multicenter Trial 555 patients 325 mg 4 times 30%
daily for 2 years
Table 3: Percent reductions in cardiovascular events among patients with suspected acute
evolving myocardial infarction and acute nonfatal myocardial infarction.
Nonfatal myocardial infarction 31 49
Nonfatal stroke 39 46
Cardiovascular mortality 15 23
Cardiovascular events 25 28
Endpoint Percent reductions in patients assigned antiplatelet therapy
Antiplatelet Trialists’ Collaboration 2nd International Study of Infarct Survival
(long-term therpy; 1-3 years) (short-term therapy; 5 weeks)
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stroke amongst patients involved in
antiplatelet studies was too small to
permit any comparison amongst
different aspirin dosage regimens.
However, the UK-TIA Trial did observe a
dose-response relation for extracranial
haemorrhagic events, with an increased
incidence of gastrointestinal
haemorrhage at higher doses (5%
incidence for patients taking 1200 mg
aspirin daily, as against 3% for those
taking 300 mg daily), possibly
reflecting the presence of more severe
gastric mucosal damage and thus a
higher possibility of gastric bleeding.
Long-term administration of aspirin
may also be associated with an
increased risk of chronic renal disease
and interference with blood pressure
control in hypertensive individuals,
since prostaglandin G/H synthase is
involved in the renal synthesis of
vasodilatory prostaglandins. While the
use of aspirin at sub-antiinflammatory
doses is unlikely to exert any effect
(aspirin is only a weak inhibitor of
renal prostaglandin synthase), the UK-
TIA trial noted elevations in systolic
blood pressures in patients on 300 mg
and 1200 mg aspirin daily. Furthermore,
this effect of aspirin in both renal and
other peripheral tissues interferes with
the action of angiotensin-converting-
enzyme (ACE) inhibitors in controlling
hypertension.
Conclusions
The benefits to be derived from
long-term aspirin therapy are evident,
particularly in secondary prevention of
cardiovascular events. The progress in
the understanding of the underlying
mechanism of action of the drug and
its dose-response relationship have led
to the current recommendations of an
initial loading dose of about 300 mg
followed by a daily dose of 75 mg, the
latter serving to decrease the possible
incidence of side effects.
While the role of prescribing aspirin
antiplatelet therapy and monitoring of
its cardiovascular effects remain strictly
that of the physician, the pharmacist,
too, has a contribution to make. There
exists the danger of the idea spreading
among the general population that “an
aspirin (or baby aspirin) tablet a day is
good for one’s health”. Such an idea is,
at the very least, questionable in the
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absence of predisposing health
conditions and becomes certainly more
so if the possibility of side effects and
drug interactions discussed above is
prevalent.
Nonetheless, the pharmacist remains
in an ideal position to identify
candidates in whom initiation of such
therapy appears feasible, and should
take it upon himself/herself to consult
with and make recommendations to the
patient’s physician, particularly where
administration of an aspirin
antiplatelet dosage regimen might be
effective in the prevention of
cardiovascular events. ✱
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1. Platelet aggregation is
caused by release of:
a) prostaglandin G2
b) prostaglandin synthase
c) thromboxane A2
d) acetylsalicylic acid
2. A once daily aspirin
antiplatelet regimen is
effective because:
a) very high doses of aspirin
are used
b) the drug accumulates
intracellularly from where
it is gradually released
c) sustained release
preparations are used
d) recovery from the effects
of aspirin is related to
platelet turnover
3. Aspirin is effective as a
primary preventive agent
in:
a) hypertensive patients
b) perfectly healthy
individuals
c) patients with chronic
stable angina
d) both (a) and (c)
4. The minimum aspirin
dose effective in
secondary prevention in
patients with unstable
angina is:
a) 324 mg daily
b) 75 mg daily
c) 1200 mg daily
d) subject to debate
5. The minimum aspirin
dose effective in
secondary prevention in
patients with a history of
transient ischaemic
attacks is:
a) 324 mg daily
b) 75 mg daily
c) 1200 mg daily
d) subject to debate
6. In order for a beneficial
effect to be observed
with aspirin therapy in
patients with acute MI,
therapy must last for at
least:
a) about 3 years
b) about 2 years
The Antiplatelet Activity of Aspirin
Assessment Questions:
c) about 1 year
d) slightly more than 1
month
7. Aspirin can prevent
arterial or graft occlusion
after:
a) coronary artery surgery
b) coronary artery
angioplasty
c) formation of a
haemodialysis shunt
d) all of the above
8. The highest benefit in
reduction of deep vein
thrombosis and
pulmonary embolism is
seen in:
a) all medical and surgical
patients
b) all surgical patients
c) general and orthopaedic
surgery patients
d) all medical patients
9. The major underlying
mechanism responsible
for the side effects of
aspirin is:
a) direct erosion of the
intestinal lining, since
aspirin is an acid
b) inhibition of the
constitutive
prostaglandin synthesis
pathway
c) metabolism by the liver
to toxic metabolytes
d) none of the above
10.Gastrointestinal
complications with
aspirin:
a) occur more frequently at
higher doses
b) occur less frequently at
lower doses
c) exhibit a dose-dependent
response
d) all of the above
11.Aspirin-mediated
inhibition of
prostaglandin synthesis:
a) has no effect on blood
pressure control in
hypertensive individuals
b) can result in undesirable
drug interactions with
captopril and enalapril
c) has been observed to
result in elevations in
diastolic blood pressure
d) probably occurs even at
maintenance doses of 75
mg daily.
12.The recommended aspirin
dosage regimen for
antiplatet therapy is:
a) an Alka-Seltzer tablet
daily
b) 300 mg aspirin q.i.d.
c) an initial loading dose of
about 300 mg followed
by a daily dose of 75 mg
d) none of the above
13.The minimal aspirin dose
which will result in
practically total
suppression of platelet
thromboxane A2
biosynthesis is:
a) 75 mg
b) 100 mg
c) 300 mg
d) 1200 mg
14.The gastrointestinal side
effects associated with
prolonged use of high
dose aspirin include:
a) stomach pain
b) heartburn
c) diarrhoea
d) both (a) and (b)
15.If a patient asks a
pharmacist whether it is
recommendable to take
an aspirin tablet a day
for good health, the
pharmacist should:
a) answer with an
unequivocal yes
b) check if the patient is
hypertensive or has a
history of cardiovascular
events
c) refer to a physician
d) both (b) and (c)
16.Aspirin plays a major role
in preventing secondary
cardiovascular events in
patients with:
a) unstable angina
b) a history of acute
myocardial infarction but
not nonacute MI
c) a history of any form of
MI
d) both (a) and (c)
17.The main indicators in
the effectiveness of
aspirin in both primary
and secondary prevention
of occlusive
cardiovascular disease
are:
a) decrease in mortality
b) decrease in incidence of
MI
c) both of the above
d) none of the above
18.How does the
combination of aspirin
with intravenous
streptokinase compare
with the use of either
agent alone in promoting
survival following MI?
a) The combination is more
effective
b) The combination is less
effective
c) The combination is
equally effective
d) There is no clear evidence
for a conclusion to be
reached.
19.Other drugs which are
sometimes combined
with aspirin for
antiplatelet activity
include:
a) dipyridamole
b) enalapril
c) sulfinpyrazone
d) both (a) and (c)
20.The incidence and
severity of
gastrointestinal
complications associated
with long-term aspirin
use are effected by:
a) dosage regimen
b) duration of treatment
c) the type of formulation
used
d) all of the above
Select only ONE option in each question
by ticking the respective box
on the Response Sheet (page 39).
